Device Trial Radar · NCT04295811
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
784
Actual
Start
Jun 18, 2020
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Lucid Diagnostics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 5, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- Male only, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Conditions
- Barrett Esophagus
- Esophageal Adenocarcinoma
- Barretts Esophagus With Dysplasia
- Barrett's Esophagus Without Dysplasia
Interventions
EsoGuard (lab assay)Device
EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
EsophagogastroduodenoscopyDiagnostic test
Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EfficacyTime frame: Per subject analysis through study completion which is up to approximately 5 weeks
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
Lucid Investigative Site
Aurora, Colorado
Lucid Investigative Site
Englewood, Colorado
Lucid Investigative Site
Washington D.C., District of Columbia
32 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.